Emerging treatments

Your Organisational Guidance

ebpracticenet urges you to prioritise the following organisational guidance:

Oncogenetische testen voor familiale adenomateuze polyposePublished by: KCELast published: 2014Dépistage oncogénétique de la polypose adénomateuse familialePublished by: KCELast published: 2014

Erlotinib

One pilot trial reported that a combination of sulindac (a non-steroidal anti-inflammatory drug) and low-dose erlotinib (a tyrosine kinase inhibitor) may reduce duodenal polyp burden in patients with FAP, but additional studies are needed to assess both long-term benefit and side-effect profile.[61]

TP-252

TP-252 is a novel mineral amino acid-based derivative of eicosapentaenoic acid (EPA) that delivers high plasma levels of EPA free fatty acid (EPA-FFA). A study has shown that EPA-FFA has a role as a chemopreventive agent in FAP, to a degree similar to that previously observed with selective cyclo-oxygenase-2 inhibitors.[62] TP-252 has been granted orphan drug status by the US Food and Drug Administration and clinical trials in the US will study TP-252 as an adjunct therapy to endoscopic surveillance for the treatment of young patients with FAP. TP-252 may prove to be useful to delay colectomy in order to allow transition into adulthood with an intact colon, for social and functional reasons. Therapy that may safely delay colectomy in adolescents with FAP within high-risk desmoid families may also be appealing in order to minimise the risk of desmoid formation associated with surgical trauma. 

Use of this content is subject to our disclaimer